You are viewing the site in preview mode

Skip to main content
Fig. 3 | Virology Journal

Fig. 3

From: Effectiveness of azvudine versus nirmatrelvir/ritonavir for hospitalized patients with SARS-CoV-2 infection and pre-existing liver diseases

Fig. 3

The efficacy of Azvudine vs Paxlovid in reducing composite disease progression. A Cumulative risk curve; B Incidence rate of composite disease progression outcome with multivariate Cox regression analysis after adjusting for other confounding factors; C The effectiveness of Azvudine vs Paxlovid in reducing the risk of composite disease progression by subgroups of selected baseline characteristics. HR: Hazard Ratio; 95%CI: 95% confidence interval

Back to article page

Virology Journal

ISSN: 1743-422X